What Is a NAD+ Injection? The Definition, and the Evidence

A NAD+ injection is a shot of nicotinamide adenine dinucleotide — the coenzyme itself, not a precursor — delivered under the skin (subcutaneous) or into a muscle (intramuscular), usually from a compounded vial on a daily or several-times-weekly schedule. It is sold as a faster, cheaper, at-home version of the IV drip, marketed for energy, focus, recovery and anti-aging. In the US it is a compounded product, not an FDA-approved medicine.

That is the definition. The harder question, and the one worth answering before you order a vial, is: what does the research actually show for injecting NAD+ — and how does that differ from the better-studied oral precursors?

The honest answer is that NAD+ injections sit at the thin end of the evidence. They are largely a clinic- and telehealth-marketed product, not a trialed intervention. This page lays out what is genuinely known, where the marketing outruns the science, and what a course typically costs — so you can decide with clear eyes.

What is a NAD+ injection, in detail

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell. It shuttles electrons through the reactions that convert food into cellular energy, and it also fuels DNA-repair enzymes and the sirtuin proteins, which is why it sits at the center of metabolism and ageing biology ¹. NAD+ availability tends to fall with age — human-tissue work has documented age-associated declines in NAD+ alongside rising oxidative stress ² — and that decline is the entire rationale behind "NAD+ restoration."

A NAD+ injection takes that idea and delivers NAD+ itself — not a precursor — under the skin (subcutaneous) or into a muscle (intramuscular), usually as a small daily or several-times-weekly dose from a compounded vial. The promise is that skipping the gut and the IV chair gives you the "benefits of a drip" in a self-administered shot. Whether that promise holds is exactly what the evidence has to settle.

One naming point, because it changes what people expect of the product: you will usually find NAD+ on a clinic menu headed "peptide therapy," beside sermorelin and BPC-157. NAD+ is not a peptide — it is a dinucleotide, and it contains no amino acids at all. The grouping is a merchandising decision based on shared vials and syringes, and it quietly lends the injection an evidence halo that belongs to approved peptide drugs like insulin. We take that apart in is NAD+ a peptide?.

The core problem: there are no outcome trials of injected NAD+

Stated as plainly as possible: there is no rigorous randomized controlled trial showing that subcutaneous or intramuscular NAD+ improves energy, focus, recovery, or any aging-related outcome in humans. Not a single published outcome RCT exists for the injectable route. That isn't a hostile framing — it's simply where the literature stands.

The closest human data on putting NAD+ directly into the body (rather than swallowing a precursor) comes from a single 2019 pilot of intravenous NAD+, which tracked the plasma and urine NAD+ metabolome during a 6-hour infusion ³. Even there, free NAD+ was largely undetectable in blood for hours as the body metabolized it — and the study measured biochemistry, not whether anyone felt or performed better. There is no comparable pharmacokinetic study for subcutaneous or IM NAD+ at all, let alone a clinical-outcome trial. So when a clinic markets injections as "proven," that claim is not anchored to a trial of injections.

The better-studied path: oral NMN and NR precursors

To see what raising NAD+ can — and can't — realistically do, you have to look at the route that actually has trials: oral precursors, nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). This is the crucial distinction the injection marketing blurs.

Oral precursors clearly hit the biochemical target. NR's pharmacokinetics in humans are well characterized — it raises blood NAD+ predictably and dose-dependently ⁴. Oral NMN reliably raises blood NAD+ and is well tolerated in a dose-ranging RCT ⁵; a pharmaceutical-grade NMN formulation cleanly increased circulating NAD+ and its metabolome ⁶; and chronic NR elevates NAD+ in healthy middle-aged and older adults ⁷. So the precursors unambiguously move the biomarker.

But — and this is the part that matters most — raising the biomarker has repeatedly failed to translate into felt benefit. When NR augmented the aged human muscle NAD+ metabolome, it did not improve muscle bioenergetics or physical performance ⁸. When NR raised blood NAD+ in older adults with mild cognitive impairment, neurocognitive scores were unchanged ⁹. A systematic review and meta-analysis found the metabolic benefits of NAD+ precursors limited and inconsistent despite reliably raised NAD+ ¹⁰. The clearest positive human signal is narrow: a randomized crossover study found oral NMN improved muscle insulin sensitivity in prediabetic women ¹¹ — a specific metabolic endpoint in a specific population, not a general energy or anti-aging result. And much of the most exciting "rejuvenation" data is from mice, where long-term NMN mitigated age-associated physiological decline ¹² — striking, but not a human outcome.

The logic here is hard to escape: if the oral precursors — the ones with real RCTs — struggle to convert higher NAD+ into how people feel, an injectable route with zero outcome trials cannot honestly claim to do better. We walk through the precursor evidence in depth in our NAD+ therapy evidence pillar and compare the two precursors head-to-head in NMN vs NR.

Injections vs IV vs oral: what each route can and can't claim

It helps to line the routes up honestly:

• •Oral NMN / NR. The only route with a real human trial base. Reliably raises NAD+ ⁴⁵⁷; benefits on energy, cognition, and metabolism are modest, mixed, or null ⁸⁹¹⁰, with one narrow positive insulin-sensitivity signal ¹¹. Cheapest by far.
• •IV NAD+. Heavily marketed; one human pharmacokinetic pilot, no outcome RCTs ³. Expensive and time-consuming. See our NAD+ IV therapy evidence and cost guide.
• •Subcutaneous / IM injections. No human pharmacokinetic study and no outcome RCT specific to the route. Positioned as a cheaper, at-home alternative to IV, but its evidence base is thinner than IV's, not stronger.

The marketing instinct is to treat these as interchangeable — "it's all NAD+." Pharmacologically the route matters enormously, and on evidence the injectable route is the least studied of the three, not a validated shortcut. (We put the three routes side by side on bioavailability, cost, and evidence in NAD+ IV vs injection vs oral.) The same gap applies to the "instant energy" claims attached to shots; we break those down in does NAD+ boost energy. And the same evidence gap haunts the oral end of the market too: products that wrap NAD+ in fat bubbles to "survive the gut" have no human absorption data either, as we cover in does liposomal NAD+ really absorb orally?. The needle-free nasal route is no better evidenced — its only data is animal brain-injury research, never tested in people, as we explain in can NAD+ nasal spray absorb through the nose?.

Side effects and safety

The most reliable, well-documented effect of parenteral NAD+ is, ironically, its side effects during administration. In the IV pilot, infusing NAD+ too quickly provoked chest tightness or pressure, flushing, nausea, cramping, and lightheadedness — which is precisely why the infusion was stretched over hours ³. Subcutaneous and IM injections are typically smaller per-dose, but users commonly report injection-site reactions, flushing, and a transient "rushing" or nauseated feeling — consistent with the same dose-rate sensitivity. We compare what to expect across every route in our guide to NAD+ side effects by route.

One practical consequence of that dose-rate sensitivity is worth stating, because it is where at-home injecting actually goes wrong. Compounded NAD+ is prescribed in milligrams but drawn in insulin units, and the conversion depends entirely on how much bacteriostatic water the pharmacy put in the vial — change the diluent and the same dose lands on a completely different mark. Our NAD+ injection dosage calculator does that arithmetic (and deliberately refuses to invent a dose, since no trial has ever set one).

On longer-term safety, what reassurance exists again comes from the oral literature: a dedicated trial of high-dose NR (NR-SAFE) found it generally safe and well tolerated ¹³, and tolerability has been consistent across the oral NMN and NR trials. But "safe in oral trials" does not transfer automatically to repeated injection of NAD+, which has not been studied for long-term safety. Because injectable NAD+ in the US is compounded (it is not an FDA-approved finished drug), product quality, sterility, and dosing accuracy depend on the compounding pharmacy — so clinical oversight and a reputable source matter. Anyone who is pregnant, has a medical condition, or takes other medications should clear it with a clinician first; this is consumer education, not medical advice.

What NAD+ injections typically cost

Injections are marketed partly on cost — cheaper than an IV drip — but they are not cheap relative to the route that actually has evidence. Pricing is set entirely by clinics and telehealth services; there is no insurance coverage, because injectable NAD+ is not an approved treatment for any condition.

Typical real-world US pricing looks roughly like this:

• •Compounded subcutaneous/IM NAD+ vials via telehealth commonly run about $150–$400+ per month, depending on dose and program, often bundled with a provider consult fee. What each provider publishes — and which of them attach a qualifier to the headline figure — is recorded verbatim in our NAD+ price index.
• •In-clinic injection visits are usually priced per shot and add up similarly or more over a month.
• •That still undercuts IV NAD+ (often $300–$1,000+ per single infusion, with multi-session protocols reaching the low thousands), which is the comparison clinics lean on.

But the honest comparison isn't injection-vs-IV — it's injection-vs-evidence. Oral NMN or NR, the routes with actual human trials showing they raise NAD+, typically cost a fraction of an injection program per month. So with injections you're paying a premium for an unproven delivery method, not for better-proven results.

The bottom line

NAD+ injections are a compounded, clinic- and telehealth-marketed product whose promotion far outruns its evidence. There are no randomized controlled trials — and not even a human pharmacokinetic study — showing that subcutaneous or intramuscular NAD+ improves energy, focus, recovery, or aging. The only human data on delivering NAD+ directly is a single IV pharmacokinetic pilot that measured biochemistry, not outcomes ³. The credible evidence that NAD+ can be raised at all comes from inexpensive oral precursors — and even those reliably move the biomarker without reliably improving how people feel or function ⁸⁹¹⁰.

If you're drawn to NAD+, the evidence-based move is to understand the whole picture before paying for a shot. Start with our NAD+ therapy evidence pillar, compare the precursors in NMN vs NR, see how the IV route really stacks up in our NAD+ IV therapy guide, and check how products and providers compare on our NAD+ rankings hub. If you've already decided to try a shot, our guide to finding a legit NAD+ injection provider near you covers how to vet a clinic or telehealth service and what it costs. For the one delivered-NAD+ use with a real human trial behind it — sudden hearing loss — see NAD+ for hearing loss and tinnitus. Treat injectable NAD+ as an expensive, unproven option — not the proven shortcut it's sold as.